AstraZeneca/Sanofi's Beyfortus get 1st approval in EU to prevent RSV infection in infants

Nov. 04, 2022 4:37 AM ETSanofi (SNY), AZNGSK, PFEBy: Ravikash, SA News Editor2 Comments

AstraZeneca production plant

Roland Magnusson/iStock Editorial via Getty Images

The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) and Sanofi's (NASDAQ:SNY) antibody therapy Beyfortus to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.

The British

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.